UBS Nearly Doubles Its Price Target on Clover Health (CLOV)

With EPS growth for the next five years forecasted at 51.31%, Clover Health Investments, Corp. (NASDAQ:CLOV) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade.

On June 11, UBS analyst Jonathan Yong raised his price target on Clover Health Investments, Corp. (NASDAQ:CLOV) to $4.75 from $2.75 while maintaining a Neutral rating. The significant increase in the valuation reflects improving confidence in the company’s operating outlook as Clover Health continues to execute on initiatives designed to enhance profitability and expand the capabilities of its technology-enabled healthcare platform. Although UBS remains cautious on the shares, the revised target acknowledges the company’s improving business fundamentals.

Earlier, on June 4, Canaccord raised its price target on Clover Health Investments, Corp. (NASDAQ:CLOV) to $4.20 from $3.20 while reiterating a Buy rating. The firm stated that its investment thesis for 2026 continues to gain traction as improving conditions across the managed care industry are benefiting both insurers and digital healthcare providers. Canaccord highlighted strong operating performance during April and May, noting that these trends have contributed to meaningful appreciation in the shares and reinforced confidence in Clover Health’s ability to continue improving financial performance.

Founded in 2014 and headquartered in Franklin, Tennessee, Clover Health Investments, Corp. (NASDAQ:CLOV) is a healthcare technology company and Medicare Advantage insurer. Improving analyst sentiment, growing confidence in the managed care environment, and a projected five-year EPS growth rate of 51.31% position Clover Health as one of the best quality stocks to buy and hold for the next decade.

READ NEXT: 7 Best Fusion Energy Development Stocks to Buy and 7 Best Battery Technology Stocks to Buy for Grid Storage.

Disclosure: None.  Follow Insider Monkey on Google News.